The global cerebral artery syndrome treatment market is estimated to grow at a notable CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing incidences of stroke, along with growing geriatric population across the globe. Cerebral artery is the terminal branch of internal carotid artery, which supplied blood to the frontal, temporal, and parietal lobes of the brain. Cerebral artery syndrome refers to the blockage of cerebral artery, obstructing blood supply to the middle brain. This causes hindrance to various functions controlled by this part of the brain, such as, primary motor of the face, trunk, and upper limbs. The causes of cerebral artery syndrome include hypertension, uncontrolled diabetes, smoking, fatty diet, and stressful lifestyle. According to the data by the International Diabetes Federation, approximately 463 million adults aged 20 to 79 years were suffering from diabetes in 2019, disturbingly this number will rise to 700 million by 2045. According to the data by the World Health Organization, around 1.28 billion adults suffer from hypertension, globally, as of 2021. Moreover, 46% adults are unaware that they have hypertension. It is more common in older adults, owing to the high levels of bad cholesterol in their bodies, and lack of physical activities. This is estimated to boost the market growth.
The market is segmented by distribution channel into hospital, specialty clinic, pharmacies, and others, out of which, the hospital segment is anticipated to hold the notable share in the global cerebral artery syndrome treatment market over the forecast period on account of growing patient pool of this syndrome, and presence of large number of hospitals providing advance healthcare services. Hospitals have higher acceptance amongst the public, which is estimated to boost the market growth. CLICK TO DOWNLOAD SAMPLE REPORT
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global cerebral artery syndrome treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the increasing population of older adults, and favorable healthcare reimbursement and insurance policies. The market in Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of highest geriatric population in the highly-populated countries, such as, India and China. According to the data by the World Bank, in India, 6.574% of the total population aged above 65 years, in 2020. Similarly, in China, 11.96% of the total population aged above 65 years in the same year. This is estimated to boost the regional market growth.
The global cerebral artery syndrome treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global cerebral artery syndrome treatment market includes the following segments:
FREQUENTLY ASKED QUESTIONS
Rising incidences of diabetes and hypertension, backed by poor lifestyle is estimated to boost the market growth.
The market is anticipated to attain a notable CAGR over the forecast period, i.e., 2022 – 2030.
Lack of healthcare facilities in low-income economies are estimated to hamper the market growth.
The North America region is estimated to gain the largest market share owing to the high investment in R&D activities, along with presence of major market players in the region.
The major players in the market are Merck & Co., Inc., Siemens Healthcare GmbH, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., Baxter International, Inc., Novartis AG, Sanofi-aventis Groupe, and AbbVie Inc.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by treatment, distribution channel, and by region
The hospital segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization